Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Craiu, Dana
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Musetescu, Mihai Cristian
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Grigore, Ioana
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Chioncel, Camelia
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
Alexey, Sergeev
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26